Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status

BACKGROUND: Nivolumab has promising efficacy for the treatment of non‐small cell lung cancer (NSCLC). Various predictive factors for nivolumab response in those with NSCLC have been reported, including performance status (PS). The objective of this retrospective study was to determine the predictive...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Adachi, Yuichi, Tamiya, Akihiro, Taniguchi, Yoshihiko, Enomoto, Takatoshi, Azuma, Kouji, Kouno, Shunichi, Inagaki, Yuji, Saijo, Nobuhiko, Okishio, Kyoichi, Atagi, Shinji
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013052/
https://ncbi.nlm.nih.gov/pubmed/31880861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2807
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars